Physician profile
Philip Maher
NPI 1619239795
$950.89
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.35 · 2021: $345 · 2022: $507 · 2023: $59.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.04 | 2021-2022 | |
| Amgen INC. | $109.86 | 2021-2022 | |
| Lilly USA, LLC | $83.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.30 | 2022 | |
| Abbvie INC. | $66.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.14 | 2021-2023 | |
| Glaxosmithkline, LLC. | $58.38 | 2020-2023 | Trelegy Ellipta |
| Boston Scientific Corporation | $57.83 | 2021 | |
| Pfizer INC. | $41.99 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $38.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.15 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $33.38 | 2021-2022 | |
| Dexcom, INC. | $27.98 | 2022 | |
| Esperion Therapeutics, INC. | $25.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.33 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.81 | 2022 | |
| Amarin Pharma, INC. | $12.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.